25
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Efficacy of Delayed Granulocyte Colony-Stimulating Factor after Full Dose CHOP Therapy in Non-Hodgkin's Lymphoma: A Pilot Study for a Leukocyte Count Oriented Regimen

, , , , , , & show all
Pages 103-109 | Received 15 Feb 1995, Published online: 01 Jul 2009

References

  • Armitage J. O., Corder M. P., Leimert J. T. Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) without maintenance therapy. Cancer Treat. Rep. 1980; 64: 649–654
  • Coltman C. A., Dahlberg J., Jones S. E. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year South West Oncology Group Follow Up. Proc. Nat. Acad. Sci. USA 1986; 5, 774 (abstr)
  • McKelvey E. M., Gottlieb J. A., Wilson H. E. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
  • Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution. Ann. Int. Med. 1985; 103: 140–142
  • Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Ganellos G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann. Int. Med. 1986; 104: 757–765
  • Fisher R. I., Devita V. T., Hubbard S. M. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc. Am. Soc. Clin. Oncol. 1984; 3: 242
  • Klimo P., Connors J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Int. Med. 1985; 102: 596–602
  • Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 328: 1002–1006
  • Duhrsen U., Villeval J. L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–2081
  • Neidhart J. A. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification. Cancer 1992; 70, (suppl), 913–920
  • Demuynck H., Pettengell R., De Campos E., Dexter T. M., Testa N. G. The capacity of peripheral blood stem cells mobilized with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur. J. Cancer 1992; 28: 381–386
  • Teshima T., Harada M., Takamatsu Y., Makino K., Taniguchi S., Inaba S., Kondo S., Tanaka T., Akashi K., Minamishima I. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 1992; 10: 215–220
  • Hohaus S., Goldschmidt H., Ehrhardt R., Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exper. Hematol. 1993; 21: 508–514
  • Pettengell R., Testa N. G., Swindell R., Crowther D., Dexter T. M. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239–2248
  • Hryniuk W. M. The importance of dose intensity in outcome of chemotherapy. Importance Advances in Oncology, S. Hellman, V. Devita, S. (eds.). Rosenberg, 1988; 121–141
  • Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529–533
  • The non-Hodgkin's lymphoma pathologic classification project. National cancer institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
  • Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
  • Tsakona C. P., Khwaja A., Goldstone A. H. Does treatment with haemopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients?. Bone Marrow Transplant. 1993; 11: 433–436
  • Hovgaard D. J., Nissen N. I. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leukemia and Lymphoma 1992; 7: 217–224
  • Hovgaard D. J., Nissen N. I. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: A phase I/II study. J. Clin. Oncol. 1992; 10: 390–397
  • Pettengell R., Gurney H., Radford J. A., Deakin D. P., James R., Wilkinson P. M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
  • Gulati S. C., Bennett C. L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann. Int. Med. 1992; 116: 177–182
  • Gianni A. M., Bregni M., Siena S., Magni M., Di-Nicola M., Lombardi F., Tarella C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J. Clin. Oncol. 1992; 10: 1955–1962
  • Ikebuchi K., Ihle J. N., Hirai Y., Wong G. G., Clark S. C., Ogawa M. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by IL-1, IL-6, and G-CSF. Blood 1988; 72: 2007–2014
  • Morstyn G., Campbell L., Lieschke G. J., Layton J. E., Maher D., O'Connor M., Green M., Sheridan W., Vincent M., Alton K. Abrogation of chemotherapy induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989; 7: 1554–1562
  • Khwaja A., Mills W., Leveridge K., Goldstone A. H., Linch D. C. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant. 1993; 11: 479–482
  • Meisenberg B. R., Davis T. A., Melaragno A. J., Stead R., Monroy R. L. A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to non-human primates after high-dose chemotherapy. Blood 1992; 79: 2267–2272

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.